INMED PHARMACEUTICALS INC. Finite-Lived Intangible Asset, Expected Amortization, Year One
INMED PHARMACEUTICALS INC. (INM) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $162.75 thousand as of 2026-03-31, per its S-4 filed 2026-07-02.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2026-07-02
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $162.75K.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $162.75K.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $162.75K.
- 2025-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $162.75K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2026-03-31 | $162.75K S-4 · filed 2026-07-02 |
| 2025-09-30 | $162.75K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $162.75K S-4 · filed 2026-07-02 |
| 2025-03-31 | $162.75K 10-Q · filed 2025-05-12 |
| 2024-09-30 | $162.75K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $162.75K 10-Q · filed 2025-02-12 |
| 2023-12-31 | $158.94K 10-Q · filed 2024-02-13 |
| 2023-09-30 | $117.94K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $158.94K 10-K · filed 2023-09-29 |
| 2023-03-31 | $39.23K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $78.42K 10-Q · filed 2023-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |